April 25, 2022
Shionogi said on April 22 that an interim analysis of a large-scale Japan PII/III trial for its COVID-19 vaccine S-268019, which covered more than 3,000 patients, confirmed no serious safety concerns and an increase in neutralizing antibody titers. The study...read more